Verônica Silva Vilela1, Giselle Baptista Maretti2, Lívia Marques da Silva Gama3, Claudia Henrique da Costa3, Rogério Lopes Rufino3, Roger A Levy2. 1. Disciplina de Reumatologia, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil. Electronic address: veronicavilelavs@yahoo.com.br. 2. Disciplina de Reumatologia, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil. 3. Disciplina de Pneumologia, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro (UERJ), RIo de Janeiro, RJ, Brazil.
Abstract
Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. OBJECTIVE: This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center. PATIENTS AND METHODS: We retrospectively evaluated medical records of all patients with SSc who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous, and pulmonary involvement data and laboratory results before and six months after the first infusion of RTX were collected. RESULTS: Ten patients received treatment during the study period and were included in this series. All patients had a diffuse form of the disease. Five patients suffered from an early (duration of disease shorter or equal to four years), rapidly progressive disease, and another five received RTX at late stages of the disease. In both groups of patients, stabilization of the pulmonary picture was observed, with a fall in the skin score in those patients with early forms of the disease. DISCUSSION: Similar to findings in previous studies, RTX was effective in treating early and rapidly progressive forms of SSc. We also found that patients with long-term illness may benefit from the treatment.
Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Although cyclophosphamide is effective for severe and refractory cases, there is demand for new treatments. The biological treatment with B-cell depletion with rituximab (RTX) has demonstrated efficacy for this demand in open-label studies. OBJECTIVE: This study was conducted with the aim to retrospectively evaluate all patients who used RTX for the treatment of SSc in our center. PATIENTS AND METHODS: We retrospectively evaluated medical records of all patients with SSc who used RTX to treat this disease from January 2009 to January 2015. Systemic, cutaneous, and pulmonary involvement data and laboratory results before and six months after the first infusion of RTX were collected. RESULTS: Ten patients received treatment during the study period and were included in this series. All patients had a diffuse form of the disease. Five patients suffered from an early (duration of disease shorter or equal to four years), rapidly progressive disease, and another five received RTX at late stages of the disease. In both groups of patients, stabilization of the pulmonary picture was observed, with a fall in the skin score in those patients with early forms of the disease. DISCUSSION: Similar to findings in previous studies, RTX was effective in treating early and rapidly progressive forms of SSc. We also found that patients with long-term illness may benefit from the treatment.
Authors: Verônica Silva Vilela; Bruno Rangel Antunes da Silva; Cláudia Henrique da Costa; Agnaldo José Lopes; Roger Abramino Levy; Rogério Rufino Journal: BMC Res Notes Date: 2018-12-10